EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Implementation of Clinical Trial Regulation – Update on EU-CT portal and database

Presented by Laura Pioppo
Scientific Administrator
Clinical and Non clinical Compliance

The Clinical Trial (CT) Regulation: what is new?

EUROPEAN MEDICINES AGENCY

Before May 2004

Different processes and requirements for clinical trial authorisations in each Member States…

… resulted in delays and complications detrimental to effective conduct of clinical trials in the EU.

Directive 2001/20/EC (CT Directive)



First step to harmonise processes and requirements for clinical trial authorisations.

Implementation 1 May 2004.

Concerns expressed soon after its implementation.

Regulation (EU) No. 536/2014 (CT Regulation)



Published on 27 May 2014.

Application 6 months after confirmation published in the OJ of full functionality of EU portal and EU database, in any event not earlier than 28 May 2016.

Transitional arrangements.

The Clinical Trial Regulation: what is new?

EUROPEAN MEDICINES AGENCY

CT Directive versus CT Regulation

Implemented in national laws



Directly applicable

Objectives of new CTR

- To protect the rights, safety, dignity and well-being of subjects and the reliability and robustness of the data generated in the CT;
- To foster innovation and simplify the clinical trial application process, in particular for multistate trials;
- To increase transparency, keeping the balance between protecting public health and fostering the innovation capacity of European medical research while recognising the legitimate economic interests of the sponsors.
- Overall objective: Make EU attractive for R&D.

Scope of Regulation (EU) No. 536/2014

EUROPEAN MEDICINES AGENCY

- **Unchanged scope:**
  - **Interventional clinical trials with medicinal products for human use**
  - **NEW** category of low-intervention clinical trials with adapted requirements.
    - The investigational medicinal products (IMP) are authorised and used according to the terms of MA;
    - If the IMP is not used in accordance with the terms of the MA, that use is supported by published scientific evidence on S&E;
    - Minimal additional risk or burden to the safety of the subjects compared to normal clinical practice.

- **Not covered:**
  - Non-interventional trials;
  - Trials without medicinal products (e.g. devices, surgery, etc).

Summary of key changes from CT Directive to CT Regulation

EUROPEAN MEDICINES AGENCY

As-is (Directive 2001/20) – EudraCT	To be (CT Regulation) - The EU portal and database
• **Multiple submissions for one trial** (1 submission per each MSC*) /**no harmonized dossier** (e-submission limited to structured data and paper based submission)	• **Single e-submission to all MSCs/harmonized dossier** for one trial & e-submission of structured data and documents by MSCs
• Double submission within a Member State Concerned (MSC): **to National Competent Authorities (NCAs) and to Ethics Committees**	
• **Individual assessment by each MSC** with no IT collaboration tool available	• **Joint assessment** for Part I facilitated by collaboration tools
• **No single MSC decision (NCA & ECs)**	• **Single MSC decision**
• Burden to NCAs in uploading information in the system	• Distribution of the burden among users
• **Limited EudraCT data availability** to the public : structured data from the application (CTA) and summary of results	• **View all CT related information**
• MSC* = member state concerned	

Key changes introduced by the CT Regulation

EUROPEAN MEDICINES AGENCY

- **Single e-submission to all MSCs** via an EU portal (accessible to MS NCAs and Ethics Committees);
- **Harmonised dossier** (Annex I to the Regulation / language of the documents decided by each MSC);
- **Coordinated assessment** between Reporting MS and MS Concerned;
- One **single decision** per Member State Concerned;
- Introducing a **risk adapted approach** by applying less stringent rules to those trials conducted with medicines which are already authorised and which pose only minimal risk compared to normal clinical practice;
- **Increasing transparency** as regards clinical trials and their outcomes;


Official Journal of the European Union

ANNEX I

APPLICATION DOSSIER FOR THE INITIAL APPLICATION

Article 81(4) of the CT Regulation

EUROPEAN MEDICINES AGENCY

4. The EU database shall be publicly accessible unless, for all or part of the data and information contained therein, confidentiality is justified on any of the following grounds:

(a) protecting personal data in accordance with Regulation (EC) No 45/2001;

(b) protecting commercially confidential information, in particular through taking into account the status of the marketing authorisation for the medicinal product, unless there is an overriding public interest in disclosure;

(c) protecting confidential communication between Member States in relation to the preparation of the assessment report;

(d) ensuring effective supervision of the conduct of a clinical trial by Member States.

Publication of data with CT regulation

EUROPEAN MEDICINES AGENCY

- Only applications on which a decision has been reached will be made public;
- All data and documents in the system will be made public with few exceptions;
- The default is always to make public at the first opportunity;
- Sponsors have options to defer the timing of publication of specific data/documents (use of deferrals will be monitored);
- Need to strike the balance between access to information and protecting the interest of sponsors
- Application of the Regulation is dependant on the completion of an independent audit to verify full functionality of the system:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000629.jsp&mid=WC0b01ac05808768df

Public website – Basic search

EUROPEAN MEDICINES AGENCY



Public website – Advanced search

EUROPEAN MEDICINES AGENCY



Public website– Search results view (*Dummy data*)

EUROPEAN MEDICINES AGENCY



Public website – Modify display options for search results

EUROPEAN MEDICINES AGENCY



Public website – Single trial view Summary (*Dummy data*)

EUROPEAN MEDICINES AGENCY

A POPULATION STUDY INTO THE PREVALENCE AND GENETIC PROFILE OF PATIENTS WITH CHRONIC PAIN WHO DO NOT RESPOND TO ORAL CODEINE A single site, pt population study into the prevalence and genetic profile of patients with chronic pain who do not respond to oral codeine.

EUCT number: 2018-532013-52-00

Download CT

Summary | Full trial information | Events | Trial results | Corrective measures | Inspection Record

Trial information

Conditions(s)	Chronic pain
Sponsor	
Therapeutic area	Body processes [G] - Genetic Phenomena [G05]
First submitted	23/02/2018
Last update	

Trial status

Start of trial			End of trial		Global end of trial	
Member state	**Trial status**	**Last update**	**Start of trial**	**Start of recruitment**	**End of recruitment**	**End of trial**
Belgium	Authorised					
Austria	Authorised					

Request removal of public information

Public website – Single trial view (Full trial information)



Public website – Events (Notifications)

EUROPEAN MEDICINES AGENCY

Download CT

Summary | Full trial information | Events | Trial results | Corrective measures | Inspection Record

Notifications

- Serious Breach (None)
- Unexpected Event (1)

View Details

	Business key	MSCs	Internal sponsor ID	Last modified	Submission date
○	UE-0868	BELGIUM, AUSTRIA			13/12/2017

- Urgent Safety Measure (1)
- Inspection report from country outside of the EAA (None)
- Temporary Halt (7)

Request removal of public information

Public website – Unexpected event detailed view

EUROPEAN MEDICINES AGENCY



Public website – Unexpected event detailed view



Public website – Trial Results (*Dummy data*)

EUROPEAN MEDICINES AGENCY

EUCT number: 2017-571366-86-00

Download CT

Summary | Full trial information | Events | Trial results | Corrective measures | Inspection Record

Trial results

▾ Summary results

View

	Version	Publication date
○	1.4 current	1/1/2012
○	1.3	1/1/2013

▸ Layperson summary results

▸ Clinical study reports

Request removal of public information

Public website – Corrective measures (*Dummy data*)

EUROPEAN MEDICINES AGENCY

View Clinical Trial

EUCT number: 2017-571366-86-00

Download CT

Summary | Full trial information | Events | Trial results | Corrective measures | Inspection Record

Corrective measures

View

	Publication date	Type	Member state concerned
○	1/2/2016	Suspend	Greece
○	1/6/2017	Revoke	French

Request removal of public information

Public website – Inspection record (*Dummy data*)

EUROPEAN MEDICINES AGENCY

View Clinical Trial

EUCT number: 2017-571366-86-00

Download CT

Summary | Full trial information | Events | Trial results | Corrective measures | Inspection Record

Inspection record

▾ Inspection record 1/1/2006 - Greece

View

	Version	Publication date
○	1.1	1/9/2014
○	1.2 current	1/6/2015

▸ Inspection record 1/1/2015 - France

Request removal of public information

Public website – Download trial information (*Dummy data*)

EUROPEAN MEDICINES AGENCY



- Trial Summary
- Full Trial Information

Full Applications Information will be included in the downloaded file

Application type	Status	Member states concerned	Submission date	Decision date
SUBSTANTIAL MODIFICATION	Authorised	Austria(Halted) Belgium(Authorised)	27/10/2017	27/10/2017
Part I				
Part II				
Austria				
Belgium				
INITIAL	Authorised	Austria(Halted) Belgium(Authorised)	27/10/2017	27/10/2017

- Events
- Trial Results
- Corrective measures
- Inspection records
- Attached documents

Download clinical trial | Cancel

Thank you for your attention

Laura.pioppo@ema.europa.eu
European Medicines Agency
30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Follow us on **@EMA_News**